Loading
Lenzilumab is an antibody that soaks up GM-CSF, a growth signal that chronic myelomonocytic leukaemia cells with RAS mutations are unusually sensitive to. It is being tested with azacitidine in this leukaemia.
Lenzilumab was developed by Humanigen and is best known for its trials in COVID-19 pneumonia. Its oncology rationale comes from the observation that CMML progenitors, especially those with NRAS, KRAS or CBL mutations, proliferate in response to very low levels of GM-CSF. The investigator-led PREACH-M trial in Australia is testing lenzilumab with azacitidine in CMML with RAS-pathway mutations, given intravenously with each azacitidine cycle, and has reported responses in early analyses.
Humanigen itself entered bankruptcy in 2024, so the drug's future depends on the academic programme and any new sponsor. The CMML page names it among the targeted approaches, with MEK inhibitors and ruxolitinib, being tested in the disease.
Neutralises granulocyte-macrophage colony-stimulating factor, the cytokine to which chronic myelomonocytic leukaemia cells with RAS-pathway mutations are hypersensitive, cutting the signal that drives their proliferation.
1.Lenzilumab binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Lenzilumab" OR ABSTRACT:"Lenzilumab" OR TITLE:"KB003" OR ABSTRACT:"KB003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Lenzilumab, not a curated reading list.
Shares Azacitidine and the tag subtype-drugs-wave.
Shares Monoclonal antibodies and the tag subtype-drugs-wave.
Shares Monoclonal antibodies and the tag subtype-drugs-wave.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine.